Clinically, high baseline exo-PD-L1 levels correlate with poor prognosis and early resistance to ICB in NSCLC and melanoma, while dynamic increases post-treatment predict durable responses—even before imaging confirmation (9). The gene discussed is CD274; the disease is melanoma.